Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K

Rhea-AI Filing Summary

Alkermes plc submitted a Rule 144 notice reporting 6,000 shares of Common Stock to be sold with an aggregate price of $180,000.00; the filing lists beneficial ownership of 166,649,934 shares as of 03/02/2026. The filing also lists recent vesting of restricted stock units: 897 on 02/23/2025, 3,952 on 02/22/2025, and 1,151 on 02/18/2025.

Insights

Equity Capital Markets Analyst

Rule 144 notice lists a planned sale of 6,000 shares at $180,000.

The filing shows a 6,000-share intended sale with an aggregate amount of $180,000.00 and reports beneficial ownership of 166,649,934 shares as of 03/02/2026. This is a routine disclosure under resale rules.

Recent RSU vesting events are disclosed (897, 3,952, 1,151 shares on 02/23/2025, 02/22/2025, and 02/18/2025). Cash‑flow treatment and buyer details are timing not provided in the excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	6000	180000.00	166649934	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2025	Vesting of restricted stock unit awards	Alkermes plc.			897	02/23/2025	Granted as part of issuer equity compensation plan
Common Stock	02/22/2025	Vesting of restricted stock unit awards	Alkermes plc.			3952	02/22/2025	Granted as part of issuer equity compensation plan
Common Stock	02/18/2025	Vesting of restricted stock unit awards	Alkermes plc.			1151	02/18/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ALKS Form 144 report say was offered for sale?

The filing reports 6,000 shares of Common Stock offered for sale with an aggregate price of $180,000.00. It lists this quantity and the aggregate amount along with an ownership figure as of 03/02/2026.

How many shares did Alkermes list as beneficially owned in the Form 144?

The filing lists 166,649,934 shares as beneficially owned as of 03/02/2026. That ownership figure appears on the same line reporting the sale quantity and aggregate price.

Were any equity awards noted in the ALKS Form 144 excerpt?

Yes. The excerpt discloses restricted stock unit vesting events: 897 vested on 02/23/2025, 3,952 on 02/22/2025, and 1,151 on 02/18/2025, granted under the issuer's equity compensation plan.

Does the Form 144 disclose the broker or sale method for ALKS shares?

The excerpt names a broker address (Merrill Lynch, 225 Liberty Street) but does not specify the method of sale. The filing shows the broker contact line but does not detail transaction mechanics in the provided text.

When were the listed restricted stock units granted or vested?

The excerpt shows vesting dates: 02/18/2025 (1,151 shares), 02/22/2025 (3,952 shares), and 02/23/2025 (897 shares). Each line states these were granted as part of the issuer's equity compensation plan.